Navigation Links
Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
Date:11/2/2007

University of Florida, Gainesville, and a lead investigator in this Phase IIb study.

About Hepatitis C

Hepatitis C is a blood-borne infectious disease of the liver and a leading cause of cirrhosis, liver cancer and the need for liver transplants. According to the Centers for Disease Control and Prevention (CDC), an estimated 4.1 million Americans (1.6 percent) have been infected with hepatitis C; 3.2 million are chronically infected. The number of new infections per year has declined from an average of 240,000 in the 1980s to about 26,000 in 2004. CDC estimates the number of hepatitis C-related deaths could increase to 38,000 annually by the year 2010, surpassing annual HIV/AIDS deaths.

About PEGASYS

PEGASYS, in combination with COPEGUS (ribavirin), are indicated for the treatment of adults with chronic hepatitis C who have compensated liver disease and have not previously been treated with interferon alpha. Efficacy has been demonstrated in patients with compensated liver disease and histological evidence of cirrhosis (Child-Pugh class A) and patients with HIV disease that are clinically stable (e.g., antiretroviral therapy not required or receiving stable antiretroviral therapy). In addition, PEGASYS in combination with COPEGUS is the first and only FDA-approved regimen for the treatment of chronic hepatitis C in patients coinfected with hepatitis C and HIV. PEGASYS is the only pegylated interferon indicated for the treatment of adult patients with chronic hepatitis B (HBeAg positive and HBeAg negative chronic hepatitis B who have compensated liver disease and evidence of viral replication and liver inflammation).

PEGASYS is dosed at 180mcg as a subcutaneous injection taken once a week. COPEGUS is available as a 200mg tablet, and is administered orally two times a day as a split dose. Roche has backed PEGASYS with the most extensive clinical research program ever undertaken in hepatitis C, with major studies initiated to advance treat
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)...  Aptuit LLC announces that Aptuit SSCI, located ... has enhanced its capabilities in the areas of ... molecules, including biologic drugs, metabolites, and polymers, through ... spectrometer. In making the announcement, Dr. ... expanded large molecule capability enhances our early development ...
(Date:8/21/2014)... , Aug. 21, 2014  Vermillion, Inc. (NASDAQ: ... on gynecologic cancers and women,s health, has appointed ... and Managed Markets. Ms. Bauzon has a ... expanding payer coverage for laboratory services companies. She has ... with PerkinElmer, Inc., where she held the position of ...
(Date:8/21/2014)... , Aug. 21, 2014  eRelevance Corporation ( ... announced today that it has completed integration with ... for Plastic Surgery and Dermatology practices. ... value to healthcare practices using Nextech," stated ... Corporation. "Using information from the EMR we are ...
Breaking Medicine Technology:Aptuit SSCI Adds Ultra High Resolution Q-TOF Mass Spectrometer for Large & Small Molecule Analyses 2Vermillion Appoints Holly B. Bauzon as VP of Sales and Managed Markets 2eRelevance Corporation Integrates with Nextech Electronic Medical Records 2
... The Center for,Translational Molecular Medicine (CTMM) - ... development of new techniques for,the diagnosis and treatment ... will receive research funding amounting to a total ... broad spectrum of small and,medium-sized enterprises, major industry ...
... March 31 CV Therapeutics, Inc.,(Nasdaq: CVTX ... the,American College of Cardiology 57th Annual Scientific Session ... in pancreatic islets isolated from animals and humans., ... GSIS seen with ranolazine may,contribute to the statistically ...
Cached Medicine Technology:Dutch Top Institute Allocates 150 Million Euro to R&D Projects Targeting Early Diagnosis and Treatment of Disease 2New Data Shows Ranexa(R) Increases Glucose-Stimulated Insulin Secretion 2New Data Shows Ranexa(R) Increases Glucose-Stimulated Insulin Secretion 3
(Date:8/22/2014)... August 22, 2014 Restore My ... and Dr. Samantha Pearson to help people discover how ... corrective vision surgery by instead improving their eyesight naturally ... investigative review. , “There’s a reason why the ... revenue each year—it’s because people just assume that it’s ...
(Date:8/22/2014)... CarePoint Health is proud to ... Geriatrics, Hospice and Palliative Care, Dr. Michelle Reisner, ... Their system welcomes Dr. Reisner to the community. ... CarePoint Health Medical Group, a comprehensive network of ... a wide range of specialties. This latest acquisition ...
(Date:8/22/2014)... Dayton Children's Hospital broke ground on a historic new, ... million campus renewal. Renderings of the exterior ... public. , The new patient tower is part of ... that meets the needs of patients, families and care providers ... Dayton Children’s unique patient care mission and offer places that ...
(Date:8/22/2014)... CO (PRWEB) August 22, 2014 ... provider of in-home care for seniors, is proud to ... Webinar Series. The upcoming webinar will feature Dr. Suzanne ... at Lenox Hill Hospital in New York City, National ... and author. The webinar will cover the issues surrounding ...
(Date:8/22/2014)... Aug. 22, 2014 (HealthDay News) -- College can be a ... of things they can do to make the most of ... time to adjust, explore, meet new people and learn to ... of student wellness and assessment at St. John,s University in ... "Not all learning takes place in the classroom. College is ...
Breaking Medicine News(10 mins):Health News:Restore My Vision Today: Review Exposes Natural Eye Restoration Guide by Dr. Sen and Dr. Samantha Pearson 2Health News:Dr. Reisner Joins CarePoint Health Medical Group 2Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 2Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 3Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 4Health News:Dayton Children's Hospital Breaks Ground on New, Eight-story Patient Care Tower 5Health News:Home Care Assistance of Centennial to Host Webinar on Heart Health, Featuring Dr. Suzanne Steinbaum 2Health News:Home Care Assistance of Centennial to Host Webinar on Heart Health, Featuring Dr. Suzanne Steinbaum 3Health News:College Prep 101 2
... the central government for denying medicos salaries for the ... higher educational institutions, and asked it to be a ... attitude of the government, a bench of judges Arijit ... Vahanvati: "you should act like a model employer. When ...
... pig fever had been diagnosed and was the cause of ... believed to be the first reported case of the disease ... the death of pigs by the Indian Veterinary Research Institute ... Divakaran. ,Reports indicate that initially the owner of ...
... There seems to be a link between the oft occurring ... ,Medical records of more than 4000 patients, below ... by British researchers .It was observed that those who had ... % tendency of developing Type 1 diabetes. ,Simon O'Neill, ...
... Using mice as an experimental animal, researchers have discovered that ... oocytes (egg) supply in their ovaries//. ,As a ... discoveries in the field of ovarian stem cell research and ... Henry's Institute and Associate Professor Jeff Kerr from Monash's Department ...
... public health emergency crisis. It is a rising killer in ... year about 5,000 people die prematurely in Canada's 11 largest ... Canada than breast cancer, prostate cancer, or motor vehicle accidents. ... quality index (AQI) in Hamilton was 67. On an average ...
... obesity-related risk factors have indicated that more the women ... risks// like hypertension, diabetes and hypercholesterolemia. ,Especially ... predisposing women to major health risks – researchers reported ... treatment are typically based on body mass index (BMI) ...
Cached Medicine News:Health News:Government Pulled up for Denying Pay to Striking Medicos 2Health News:Renewable Oocytes of Mice created hope in Human Fertility Treatment 2Health News:Obese Women are more likely to suffer from Major Health Risks 2Health News:Obese Women are more likely to suffer from Major Health Risks 3
Cannulated Interference Screws...
... Endoscopy Components, LLC offers ... Equipment "Made in Germany". ... manufactured according to ISO ... most excellent design elements ...
... provide excellent protection and ease of use. ... closer to an adhesive in molecular weight ... to maintain viscosity at high shear rates, ... for superb performance during capsulorhexis, phaco, IOL ...
... moisturizing mist for the eyes developed with ... from Oregon Health Sciences University's Casey Eye ... (2000) and dry eye patients showed, on ... volume of the eyes' tear film without ...
Medicine Products: